Cartesian Therapeutics, Inc. - Common Stock (NQ:RNAC)

7.365 +0.005 (+0.07%)

Delayed Quote Updated: 12:24 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cartesian Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >

Which stocks are gapping on Tuesday? ↗

June 09, 2026

Via Chartmill

Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus ↗

November 14, 2025

Cartesian Therapeutics shared initial data from Phase 2 trial of Descartes-08, showing potential for treating systemic lupus erythematosus.

Via Benzinga

Nvidia To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday ↗

November 14, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 27, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

September 19, 2025

Via Benzinga

Cartesian (RNAC) Q2 Revenue Drops 99% ↗

August 07, 2025

Via The Motley Fool

AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate ↗

July 24, 2025

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR antibody-positive gMG.

Via Benzinga

With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? ↗

May 27, 2025

HC Wainwright upgrades Kyverna to Buy with a $5 target, citing upcoming trial data and a strong cash position that supports a runway into 2027.

Via Benzinga

US Stocks Futures Trade Mixed Ahead Of Opening Bell: 'Preserve Capital In Conditions Of High Uncertainty,' Says Expert ↗

April 09, 2025

U.S. stock futures were volatile on Wednesday after the equities reversed gains on Tuesday following Donald Trump's 104% tariff on China.

Via Benzinga

Topics Government World Trade

Why Venus Concept Shares Are Trading Higher By Over 200%; Here Are 20 Stocks Moving Premarket ↗

April 09, 2025

Via Benzinga

Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients ↗

April 08, 2025

Cartesian reports 12-month data for Descartes-08 in myasthenia gravis; Phase 3 AURORA trial expected to begin in Q2 2025.

Via Benzinga

Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket ↗

April 04, 2025

Via Benzinga

Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases ↗

September 25, 2024

Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads.

Via Investor's Business Daily

RNAC Stock Earnings: Cartesian Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

RNAC stock results show that Cartesian Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

July 05, 2024

Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family

Via Benzinga

Cartesian Therapeutics Plummets On 'Watershed Moment' For CAR-T Drugs ↗

July 02, 2024

The company is the first to test a CAR-T drug against a placebo in patients with an autoimmune disease.

Via Investor's Business Daily

Cartesian's Autoimmune Disorder Candidate Hits Primary Goal In Mid-Stage Study, Announces Equity Raise Of $130M ↗

July 02, 2024

Cartesian Therapeutics reported Phase 2b trial results for Descartes-08 in generalized myasthenia gravis, showing significant improvements in MG Composite scores with a favorable safety profile. The...

Via Benzinga

RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q1 2024 ↗

May 08, 2024

RNAC stock results show that Cartesian Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

Cartesian Therapeutics Announces New Employment Inducement Grants

May 06, 2024

From Cartesian Therapeutics, Inc.

Via Business Wire

Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

April 23, 2024

Via Benzinga

HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday ↗

April 23, 2024

Via Benzinga

Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting

April 22, 2024

From Cartesian Therapeutics, Inc.

Via Business Wire

Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

April 16, 2024

Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 15, 2024

Via Benzinga

Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy ↗

April 10, 2024

Cartesian Therapeutics' autoimmune disease treatment with re-dosable mRNA CAR-Ts. Learn about Descartes-08, a promising anti-BCMA CAR-T therapy offering deeper, longer-lasting efficacy than current...

Via Benzinga

Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

April 04, 2024

From Cartesian Therapeutics, Inc.

Via Business Wire

Cartesian Therapeutics Announces New Employment Inducement Grants

April 04, 2024

From Cartesian Therapeutics

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

March 28, 2024

Via Benzinga

LivePerson And 2 Other Stocks Under $2 Insiders Are Buying ↗

March 19, 2024

The Dow Jones index closed higher by around 75 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q4 2023 ↗

March 07, 2024

RNAC stock results show that Cartesian Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

Via InvestorPlace

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.